Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

Koji Sasaki,Ghayas C Issa,Farhad Ravandi,Jovitta Jacob,Maria Khouri,Philip A Thompson,Naveen Pemmaraju,Hagop M Kantarjian,Patrice Nasnas,Tapan M Kadia,Nitin Jain,Jorge E Cortés ,Rebecca Garris ,Nicholas J Short ,Guillermo Garcia‐Manero ,Marina Konopleva ,Musa Yılmaz ,Susan O’brien

doi:10.1182/blood-2018-99-115271

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

Koji Sasaki, Ghayas C Issa + Show 16 more

Open Access

https://doi.org/10.1182/blood-2018-99-115271

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 3

Affiliation: The University of Texas MD Anderson Cancer Center, University of California, Irvine

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

Full Text